O'Shaughnessy Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$257K	Sell	2,440 -1,929	-44%	-$171K	﹤0.01%	1866
2025 Q4	$382K	Buy	+4,369	New	+$358K	﹤0.01%	1647
2024 Q4	–	Sell	-4,551	Closed	-$211K	–	2272
2024 Q3	$211K	Buy	+4,551	New	+$184K	﹤0.01%	1659
2021 Q4	–	Sell	-2,162	Closed	-$38K	–	2183
2021 Q3	$38K	Sell	2,162 -241	-10%	-$10.3K	﹤0.01%	1757
2021 Q2	$108K	Buy	2,403 +197	+9%	+$6.5K	﹤0.01%	1276
2021 Q1	$57K	Buy	+2,206	New	+$55.8K	﹤0.01%	1363

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

O'Shaughnessy Asset Management's PTGX Position: Q1 2026 in Review

O'Shaughnessy Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 44% in Q1 2026, selling an estimated $171K and leaving 2,440 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #1866.

O'Shaughnessy Asset Management first reported a position in PTGX in Q1 2021 and has held it in 6 quarters since. The position peaked at $382K in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

O'Shaughnessy Asset Management held 2,440 shares of Protagonist Therapeutics worth $257K as of Q1 2026.
O'Shaughnessy Asset Management sold 1,929 Protagonist Therapeutics shares in Q1 2026, an estimated $171K.
Protagonist Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q1 2026, its #1866 holding.
O'Shaughnessy Asset Management first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 6 quarters since.
O'Shaughnessy Asset Management's Protagonist Therapeutics position peaked at $382K in Q4 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2026, filed 13 May 2026.